Showing 2651-2660 of 3392 results for "".
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- The American Acne and Rosacea Society Offers #RosaceaRescues During Rosacea Awareness Monthhttps://practicaldermatology.com/news/the-american-acne-and-rosacea-society-offers-rosacearescues-during-rosacea-awareness-month/2461647/In recognition of National Rosacea Awareness Month in April, experts from the American Acne and Rosacea Society (AARS) are working to educate the public about the disease, its impact, and its treatment. Throughout the month, they are sharing #RosaceaRescues—science-backed, medically-based s
- EON Robotic Body Contouring Device Receives Additional FDA Clearance for Back and Thighshttps://practicaldermatology.com/news/eon-robotic-body-contouring-device-receives-additional-fda-clearance-for-back-and-thighs/2461629/EON Smarter Body Contouring has received FDA clearance for the back and thighs—the third FDA clearance for EON. The device was previously FDA-cleared for clinical providers to treat patients' full abdomen and flanks. Parent company Dominion Aesthetic Technologies describe
- Potential Notalgia Paresthetica Breakthrough: Oral Difelikefalin May Curb Persistent Itchhttps://practicaldermatology.com/news/potential-notalgia-paresthetica-breakthrough-oral-difelikefalin-may-curb-persistent-itch/2461553/Notalgia paresthetica—a nerve disorder characterized by a persistent itch in the upper back—is a common and underdiagnosed condition worldwide. To date, there are no U.S. Food and Drug Administration (FDA)-approved treatments specifically targeting this disorder. But a new s
- Rocatinlimab Shows Promise in ADhttps://practicaldermatology.com/news/rocatinlimab-shows-promise-in-ad/2461465/Rocatinlimab—a novel, patient-tailored monoclonal antibody therapy—showed promising results in atopic dermatitis patients both while taking the drug and up to 20 weeks after the therapy was stopped, Mount Sinai researchers reported in
- Industry Vet Curtis Cluff Named President and CFO of BioPhotas Inc.https://practicaldermatology.com/news/industry-vet-curtis-cluff-named-president-and-cfo-of-biophotas-inc/2461378/Curtis Cluff is the new President and Chief Financial Officer BioPhotas Inc., manufacturers of the Celluma series of light therapy devices. In this newly created role, Mr. Cluff will report to Patrick Johnson, Chief Executive Officer and inventor of the Celluma. &quo
- To Keep Pace with Growth, Crown Builds Out Manufacturing Complexhttps://practicaldermatology.com/news/to-keep-pace-with-growth-crown-builds-out-manufacturing-complex/2461266/Crown Laboratories is adding 60,000 square feet to its manufacturing complex in Johnson City, TN. The facility is home to PanOxyl acne wash, Blue Lizard Australian Sunscreen, and Sarna anti-itch lotion. The additional 60,000 sq. ft. will bring the Lafe Cox Drive facility
- Lumenis Has Launched triLift for Facial Stimulationhttps://practicaldermatology.com/news/lumenis-has-launched-trilift-for-facial-stimulation/2461173/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy an